Avid Bioservices Unveils State-of-the-Art Early Phase Center in Costa Mesa, California

Avid Bioservices Unveils Early Phase Center of Excellence

Avid Bioservices, a renowned organization within the biologics contract development and manufacturing space, recently celebrated the grand opening of its Early Phase Center of Excellence in Costa Mesa, California. Spanning an impressive 78,000 square feet, this cutting-edge facility is specifically designed to support early clinical programs and enhance the company's development capabilities.

In recent years, the demand for biopharmaceutical services has skyrocketed, pushing companies to seek innovative solutions to streamline their drug development processes. Avid's new center aims to meet this increasing demand by offering an end-to-end service model, which includes cell line development, upstream and downstream process development, IND enabling analytical method qualification, and early formulation characterization.

This new addition greatly boosts Avid's operational capacity, allowing it to manage a diverse range of biologics, from monoclonal antibodies to complex recombinant proteins. By integrating advanced technology platforms and workflows, Avid is focused on minimizing program risks and reducing timelines, all while ensuring that development is phase-appropriate from the very beginning.

Kenneth Bilenberg, the company's CEO, emphasized the intent behind the Early Phase Center. He stated, "Our new center is designed to help established pharmaceutical and innovative biotech companies accelerate their transition into the clinic. We wanted to create a facility where quality and stability form the foundation, allowing faster movement from scientific discovery to tangible patient impact." This statement highlights Avid's commitment to improving the efficiency and effectiveness of drug development processes.

The Early Phase Center boasts a dedicated team of experienced professionals who are hands-on in both the scientific and manufacturing processes. The team has been assembled to ensure that established platform processes are complemented by harmonized quality systems, aligning seamlessly with Avid’s commercial manufacturing facility. This strategic alignment eliminates rework and fosters a consistent progression as clinical programs advance from preclinical phases to commercial production.

Currently, the Early Phase Center of Excellence is fully operational and ready to accept new programs, positioning Avid as a powerful player in the U.S. biopharmaceutical industry. With a flawless FDA record and a strong reputation for agility, Avid is trusted by biopharmaceutical innovators across the globe.

Since its inception, Avid has demonstrated impressive metrics: over 600 batches manufactured, over 275 commercial batches delivered across 90 countries, and six approved commercial products, alongside successful inspections by various global regulatory agencies.

The establishment of this facility not only meets a pressing industry need but also reinforces Avid's dedication to fostering advancements in early drug development. As biopharmaceutical companies continue to seek avenues for expediting their research and development timelines, Avid’s Early Phase Center of Excellence is poised to make a significant impact in helping transform innovative science into effective therapies for patients in need.